BioLineRx Reports First Quarter 2020 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
BioLineRx (BLRX) Tops Q1 EPS by 62c
May 20, 2020 7:06 AM EDTBioLineRx (NASDAQ: BLRX) reported Q1 EPS of ($0.04), $0.62 better than the analyst estimate of ($0.66).
Highlights and achievements during the first quarter 2020 and subsequent period:
Completed recruitment of the triple combination arm of the COMBAT/KEYNOTE-202 study;Continued to advance the COMBAT/KEYNOTE-202 study toward progression free survival (PFS) and overall survival (OS) data in mid-2020;Received Orphan Drug Designation for motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe;Announced Notice of Allowance from USPTO for a broad patent covering motixafortide in combination with... More